Sekisui Diagnostics

Executive Summary

Sekisui Diagnostics is a UK-based contract development and manufacturing organization (CDMO) with over 40 years of experience specializing in microbial fermentation for recombinant protein production. The company provides end-to-end services, including process development, cGMP manufacturing, downstream purification, and analytical testing, primarily using E. coli and yeast expression systems. Its long track record and focused expertise position it as a reliable partner for biopharmaceutical and diagnostic companies seeking outsourced microbial fermentation capabilities. The company operates as a private entity, and its services are critical for the production of therapeutic proteins, enzymes, and diagnostic reagents. The CDMO market for microbial fermentation is growing, driven by increasing demand for biosimilars, novel biologics, and diagnostic antigens. Sekisui Diagnostics benefits from its established infrastructure and regulatory experience. However, the company faces competition from larger CDMOs and must continuously invest in capacity and technology. With no disclosed recent fundraising or public catalysts, its growth trajectory is likely steady, supported by ongoing client projects and potential expansion into new modalities. The overall outlook is positive due to the essential nature of its services and the company's deep expertise.

Upcoming Catalysts (preview)

• Q4 2026Expansion of cGMP manufacturing capacity70% success
• Q2 2027Strategic partnership with a major biopharma50% success
• TBDAdoption of continuous processing for fermentation40% success